Genetic variants regulating insulin receptor signalling are associated with the severity of liver damage in patients with non-alcoholic fatty liver disease

Gut

Volumn 59, Issue 2, 2010, Pages 267-273

  Dongiovanni, P ^a   Valenti, L ^a   Rametta, R ^a   Daly, A K ^b   Nobili, V ^c   Mozzi, E ^a   Leathart, J B S ^b   Pietrobattista, A ^c   Burt, A D ^b   Maggioni, M ^d   Fracanzani, A L ^a   Lattuada, E ^a   Zappa, M A ^a   Roviaro, G ^a   Marchesini, G ^e   Day, C P ^b   Fargion, S ^a  

^a UNIVERSITY OF MILAN   (Italy)

^b NEWCASTLE UNIVERSITY   (United Kingdom)

^c BAMBINO GESÙ CHILDREN S HOSPITAL   (Italy)

^d IRCCS   (Italy)

^e UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ECTOENZYME NUCLEOTIDE PYROPHOSPHATE PHOSPHODIESTERASE 1; GLYCINE; GLYCOPROTEIN; INSULIN RECEPTOR; INSULIN RECEPTOR SUBSTRATE 1; LYSINE; PLASMA CELL ANTIGEN 1; PROTEIN KINASE B; UNCLASSIFIED DRUG;

ADULT; ALLELE; ARTICLE; CLINICAL ASSESSMENT; CONTROLLED STUDY; DIABETES MELLITUS; DISEASE ASSOCIATION; DISEASE COURSE; DISEASE SEVERITY; DNA POLYMORPHISM; DYSLIPIDEMIA; FEMALE; FIBROSIS; GENETIC VARIABILITY; HUMAN; HUMAN TISSUE; INSULIN RESISTANCE; ITALY; LIVER BIOPSY; LIVER INJURY; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; NONALCOHOLIC FATTY LIVER; PRIORITY JOURNAL; RESTRICTION MAPPING; RISK FACTOR; SIGNAL TRANSDUCTION; UNITED KINGDOM; WESTERN BLOTTING;

ADULT; FATTY LIVER; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HUMANS; INSULIN RECEPTOR SUBSTRATE PROTEINS; INSULIN RESISTANCE; MALE; MIDDLE AGED; PHOSPHORIC DIESTER HYDROLASES; POLYMORPHISM, SINGLE NUCLEOTIDE; PYROPHOSPHATASES; RECEPTOR, INSULIN; SEVERITY OF ILLNESS INDEX; SIGNAL TRANSDUCTION;

EID: 77149168465     PISSN: 00175749     EISSN: 14683288     Source Type: Journal    
DOI: 10.1136/gut.2009.190801     Document Type: Article

References (34)

1. Browning JD, Szczepaniak LS, Dobbins R, et al. Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity. Hepatology 2004;40:1387-95.
2. Bellentani S, Saccoccio G, Masutti F, et al. Prevalence of and risk factors for hepatic steatosis in Northern Italy. Ann Intern Med 2000;132:112-17.
3. Marchesini G, Brizi M, Bianchi G, et al. Nonalcoholic fatty liver disease: a feature of the metabolic syndrome. Diabetes 2001;50:1844-50.
4. Ekstedt M, Franzen LE, Mathiesen UL, et al. Long-term follow-up of patients with NAFLD and elevated liver enzymes. Hepatology 2006;44:865-73.
5. Bugianesi E, Leone N, Vanni E, et al. Expanding the natural history of nonalcoholic steatohepatitis: from cryptogenic cirrhosis to hepatocellular carcinoma. Gastroenterology 2002;123:134-40.
6. Day CP. From fat to inflammation. Gastroenterology 2006;130:207-10.
7. Marchesini G, Bugianesi E, Forlani G, et al. Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome. Hepatology 2003;37:917-23.
8. Fracanzani AL, Valenti L, Bugianesi E, et al. The risk of severe liver disease in NAFLD with normal aminotransferase levels: a role for insulin resistance and diabetes. Hepatology 2008;48:792-8.
9. Wilfred de Alwis NM, Day CP. Genetics of alcoholic liver disease and nonalcoholic fatty liver disease. Semin Liver Dis 2007;27:44-54.
10. Valenti L, Fracanzani AL, Dongiovanni P, et al. Tumor necrosis factor alpha promoter polymorphisms and insulin resistance in nonalcoholic fatty liver disease. Gastroenterology 2002;122:274- 80.
11. Miele L, Beale G, Patman G, et al. The Kruppel-like factor 6 genotype is associated with fibrosis in nonalcoholic fatty liver disease. Gastroenterology 2008;135:282-91.
12. Valenti L, Dongiovanni P, Piperno A, et al. alpha1-Antitrypsin mutations in NAFLD: high prevalence and association with altered iron metabolism but not with liver damage. Hepatology 2006;44:857-64.
13. Romeo S, Kozlitina J, Xing C, et al. Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease. Nat Genet 2008;40:1461-5.
14. Accili D, Arden KC. FoxOs at the crossroads of cellular metabolism, differentiation, and transformation. Cell 2004;117:421-6.
15. Valverde AM, Fabregat I, Burks DJ, et al. IRS-2 mediates the antiapoptotic effect of insulin in neonatal hepatocytes. Hepatology 2004;40:1285-94.
16. Valenti L, Rametta R, Dongiovanni P, et al. Increased expression and activity of the transcription factor FOXO1 in nonalcoholic steatohepatitis. Diabetes 2008;57:1355-62.
17. Michael MD, Kulkarni RN, Postic C, et al. Loss of insulin signaling in hepatocytes leads to severe insulin resistance and progressive hepatic dysfunction. Mol Cell 2000;6:87-97.
18. Wieckowska A, Zein NN, Yerian LM, et al. In vivo assessment of liver cell apoptosis as a novel biomarker of disease severity in nonalcoholic fatty liver disease. Hepatology 2006;44:27-33.
19. Grarup N, Urhammer SA, Ek J, et al. Studies of the relationship between the ENPP1 K121Q polymorphism and type 2 diabetes, insulin resistance and obesity in 7,333 Danish white subjects. Diabetologia 2006;49:2097-104.
20. McGettrick AJ, Feener EP, Kahn CR. Human insulin receptor substrate-1 (IRS-1) polymorphism G972R causes IRS-1 to associate with the insulin receptor and inhibit receptor autophosphorylation. J Biol Chem 2005;280:6441-6.
21. Jellema A, Zeegers MP, Feskens EJ, et al. Gly972Arg variant in the insulin receptor substrate-1 gene and association with type 2 diabetes: a meta-analysis of 27 studies. Diabetologia 2003;46:990-5.
22. Bedogni G, Bellentani S, Miglioli L, et al. The Fatty Liver Index: a simple and accurate predictor of hepatic steatosis in the general population. BMC Gastroenterol 2006;6:33.
23. Kleiner DE, Brunt EM, Van Natta M, et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology 2005;41:1313-21.
24. Sesti G, Marini MA, Cardellini M, et al. The Arg972 variant in insulin receptor substrate-1 is associated with an increased risk of secondary failure to sulfonylurea in patients with type 2 diabetes. Diabetes Care 2004;27:1394-8.
25. Pizzuti A, Frittitta L, Argiolas A, et al. A polymorphism (K121Q) of the human glycoprotein PC-1 gene coding region is strongly associated with insulin resistance. Diabetes 1999;48:1881-4.
26. von Elm E, Altman DG, Egger M, et al. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. Lancet 2007;370:1453-7.
27. Novembre J, Johnson T, Bryc K, et al. Genes mirror geography within Europe. Nature 2008;456:98-101.
28. Weedon MN, Shields B, Hitman G, et al. No evidence of association of ENPP1 variants with type 2 diabetes or obesity in a study of 8,089 U.K. Caucasians. Diabetes 2006;55:3175-9.
29. Zeggini E, Parkinson J, Halford S, et al. Association studies of insulin receptor substrate 1 gene (IRS1) variants in type 2 diabetes samples enriched for family history and early age of onset. Diabetes 2004;53:3319-22.
30. Prudente S, Trischitta V. The pleiotropic effect of the ENPP1 (PC-1) gene on insulin resistance, obesity, and type 2 diabetes. J Clin Endocrinol Metab 2006;91:4767-8.
31. Hribal ML, Tornei F, Pujol A, et al. Transgenic mice overexpressing human G972R IRS-1 show impaired insulin action and insulin secretion. J Cell Mol Med 2008;12:2096-106.
32. Suzuki A, Angulo P, Lymp J, et al. Chronological development of elevated aminotransferases in a nonalcoholic population. Hepatology 2005;41:64-71.
33. Tasic I, Milojkovic M, Sunder-Plassmann R, et al. The association of PC-1 (ENPP1) K121Q polymorphism with metabolic syndrome in patients with coronary heart disease. Clin Chim Acta 2007;377:237- 42.
34. Goldfine ID, Maddux BA, Youngren JF, et al. The role of membrane glycoprotein plasma cell antigen 1/ectonucleotide pyrophosphatase phosphodiesterase 1 in the pathogenesis of insulin resistance and related abnormalities. Endocr Rev 2008;29:62-75.